Clinical Trial

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this project is to evaluate progression-free survival (PFS) of D-1553 Tablet versus Docetaxel Injection in subjects with prior standard therapy failure kirsten rat sarcoma viral oncogene (KRAS) G12C mutation positive locally advanced or metastatic non small cell lung cancer (NSCLC), progression-free survival (PFS) as assessed by the Independent Review Committee (IRC) based on RECIST 1.1 was used as the primary endpoint.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-03.
Status change: Not Yet Recruiting → Recruiting 2024-04-25
Trial Details
NCT Number NCT06300177
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Non Small Cell Lung Cancer
Enrollment 522 participants
Start Date 2024-03-28
Primary Completion 2026-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-04-26